so merck has no option but to make a serious offer. before someone else does. if data from the combo trial is indeed spectacular for LL, forcing merck to keep their cards close to their chest and delay or simply never disclose data, isnt that a clear signal to other BP that there is gold in them thar hills?

they will try to steal candy from our baby. we cant let them.

Quote:

---

We've seen the data for PD-1 (the chemokine that attaches to PD-L1 (Keytruda's target)) downregulation by maraviroc. Leronlimab also inhibits angiogenisis, anti-trafficking of tumor cells, increase in tumor fighting NKT cells, crippling DNA repair in tumor cells, stopping recruitment of Tregs (which keeps the immune system from killing tumor cells), downregulates IL-4 and IL-13 (tumor protectants), downregulates CDK2/4/6, cyclin D1, cyclin E, and PCNA which are implicated in tumor cell growth, Upregulates p27 and p53 which are both tumor suppressors.

No need to fantasize. I have no doubt that leronlimab far outclasses Keytruda and can fight cancers that Keytruda has failed in.

---